Bilateral Retinal Vein Occlusion and Rubeosis Irides: Lessons To Learn
,
Abstract
Uncontrolled hypertension is well- known to give rise to systemic complications involving multiple central organs. Artherosclerosis leads to damage of the retinal vessels wall, contributing to venous stasis, thrombosis and finally, occlusion. Retinal vein occlusions compromise vision through development of ischaemic maculopathy, macular oedema, and rubeotic glaucoma. Laser photocoagulation remains the definitive treatment for ischaemic vein occlusion with secondary neovascularization. Timely treatment with anti- vascular endothelial growth factor prevents development of rubeotic glaucoma. We hereby report an unusual case of bilateral retinal vein occlusion complicated by rubeosis irides, which was successfully managed to improve vision and prevent rubeotic glaucoma.
Jeganathan VSE, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care 2008;31(9):1905-12.
Duker JS, Brown GC: Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol1989;107(7):998-1000.
Bai Y, Ma JX, Guo J, Wang J, Zhu M, Chen Y, Le YZ. Müller cell-derived VEGF is a significant contributor toretinal neovascularization. J Pathol 2009;219(4):446-454
Wong TY, Scott IU. Retinal- vein occlusion. N Engl J Med 2010; 363(22):2135-44.
McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY. Natural history of central reinal vein occlusion; an evidence basedsystemic review. Ophthalmology 2010; 117(6): 1113-23.
Laatikainen L, Blach RK. Behaviour of iris vasculature in central retinal vein occlusion: a fluorescein angiographic study of the vascular response of the retina and the iris. Br J Ophthalmol 1977;61(4):272-77.
Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion Acta Ophthalmol 2009;87(1):77-81.
Brown DM, Campochiaro PA, Singh RP, Li Zh, Gray S, Saroj N, Rondle A Ch, Rubio RG, Yee W. Ranibizumab for macular edema following central retinal vein occlusion; six- month primary end point results of phase III study. Ophthalmol 2010; 117(6):1124-33.
Lim JW. Intravitreal bevacizumab and cytokine levelsin k=major and macular vein occlusions. Ophthalmologica 2011; 225(3): 150-4.
| Files | ||
| Issue | Vol 51, No 9 (2013) | |
| Section | Original Article(s) | |
| Keywords | ||
| Anti- vascular endothelial growth factor Retinal vein occlusion Rubeosis irides | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
